Conopco, Inc.

Other

Unilever Plc

Unilever, N.v.

Unilever IP Holdings B.v.

Unilever Global IP Limited

Thornalley, Paul John

Rabbani, Naila

Unilever Plc, a Company Registered in England and Wales Under Company No. 41424

Gail Jenkins

Linda Jane Wainwright

John Casey

Mark Ian Fowler

Alexander Gordon James

Karen Elizabeth Barrett

Naila Rabbani

Paul John Thornalley

Mingzhan Xue

Ranjit Kaur Bhogal

David James Messenger

Andrew Easson Mayes

Jennifer Elizabeth Pople

Silvina Beatriz Lotito

Magdalena Sawicka

Deborah Anne Milligan

Cleo Lucinda Bishop

Eleanor Jane Tyler

The invention relates to a composition, in particular to an oral anti-ageing composition for treating hair ageing. This invention is based on the observation that the combination of hesperetin, a flavanone, derivable from a natural rutinoside hesperetin 7-rutinoside (also known as hesperidin) in, e.g., inL,, leaves of, and trans-resveratrol synergistically up-regulates NQO-1 in a gene expression assay. The combination also induces Glo1, decreases MG and MG-protein glycation, decreases insulin resistance, decreases fasting plasma glucose, induces modest weight loss, improves renal function, decreases vascular inflammation marker slCAM-1, improves arterial dilatation and decreases the risk of cardiovascular disease. Thus is one aspect of the invention, a composition is provided, the composition comprising a combination of: (a) 30-10000, preferably 60-5000, most preferably 60-2500 mg in the form of an equivalent daily dose of flavanone of structure (I) wherein R is &#x2014;H or &#x2014;CH3, and mono-, di- and tri-acylated derivatives thereof; and (b) 20-1000, preferably 45-750, most preferably 45-500 mg in the form of an equivalent daily dose stilbenoid, wherein the composition comprises at least 0.5% w/w flavanone of structure I. 

Hesperetin and trans-resveratrol compositions and methods thereof

Disclosed is an oral or topical composition comprising a nuclear factor erythroid-2 related factor 2 agonist and a liver X receptor agonist, wherein the amounts of each of the nuclear factor erythroid-2 related factor 2 agonist and the liver X receptor agonist produce a synergistic benefit of hair fiber growth, wherein the oral or topical composition comprises &#x2264;9, preferably &#x2264;8% w/w &#x3b2;-sitosterol, wherein when the oral or topical composition comprises a catechin, the oral or topical composition comprises 0.001 to 90, preferably 0.005 to 70, most preferably 0.01 to 50% w/w catechins, wherein the oral or topical composition excludes pregnenolone, 4, 5-dihydrofuranodiene-6-one, epoxy santamarin, hydroquinone, longistyline, monacolin K, protoanemonin, N-(2,2,2-tri-fluoro-ethyl)-N-[4-(2,2,2-tri-fluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide, dihydronepetalactone, iridomyrmecin, and dihydroactinidiolide, wherein when the oral or topical composition comprises guggelsterone and epigallocatechin gallate, the oral or topical composition excludes a guggelsterone to epigallocatechin gallate weight ratio of 1 to 28, and wherein when the oral or topical composition comprises sodium dilauramide glutamide lysine, the oral or topical composition excludes 0.3% w/w sodium dilauramide glutamide lysine.

Hair composition

The invention relates to a skin anti-ageing composition. In particular a skin anti-ageing composition comprising myricetin or glycoside thereof, and at least one LXR alpha agonist. By skin ageing is meant the appearance or manifestation of any one or more of wrinkles or sagging, poor skin barrier such as dryness, scalp itch, or uneven skin tone such as age spots.

Skin anti-ageing composition

A composition which is adapted for oral consumption and which is in the form of a substantially homogeneous aqueous emulsion, suspension or dispersion comprising salicylic acid, or a C1 to C6 alkyl ester thereof, and docosahexaenoic acid (DHA) can exhibit an anti-inflammatory effect in skin.

Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin

A composition which is adapted for oral consumption comprising daidzein and an anthocyanidin, wherein the weight ratio of daidzein to anthocyanidin is in the range of from 1:1 to 1:100, wherein the daidzein is in the form of a pre-prepared aqueous dispersion, and wherein the composition is free of soy protein, which can exhibit an anti-inflammatory effect in skin, the use of a composition containing daidzein and an anthocyanidin for obtaining an anti-inflammatory effect in the skin and a method of reducing skin inflammation through the oral consumption of the composition.

Oral composition

Compositions comprising an LXR activator and retinoic acid and/or a metabolic precursor thereto are useful in reducing the effects of chronoageing and/or photoageing of the skin.

Skin treatments

This invention relates to the provision of an edible composition for the treatment of cutaneous signs of ageing, in particular those associated with loss of skin elasticity, wrinkles and sagging. Thus the inventive composition provides skin benefits selected from the group consisting of enhancing collagen deposition in the skin, reducing the appearance of wrinkles and reducing sagging. Thus the invention provides an edible composition for treating aged skin, the composition comprising: The invention also relates to a cosmetic method for providing the aforesaid skin benefits using the inventive composition.

Edible composition for treating cutaneous signs of ageing

Growing community of inventors

Sharnbrook, United Kingdom

Gail Jenkins